<?xml version='1.0' encoding='utf-8'?>
<document id="28654574"><sentence text="Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms."><entity charOffset="0-12" id="DDI-PubMed.28654574.s1.e0" text="Capecitabine" /><entity charOffset="17-26" id="DDI-PubMed.28654574.s1.e1" text="Celecoxib" /><pair ddi="false" e1="DDI-PubMed.28654574.s1.e0" e2="DDI-PubMed.28654574.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s1.e0" e2="DDI-PubMed.28654574.s1.e1" /></sentence><sentence text="For patients with unresectable or metastatic thymic epithelial neoplasms, few therapy options are available and outcomes are poor" /><sentence text=" This case series demonstrates that the combination of capecitabine and celecoxib may be a promising therapeutic option for these patients"><entity charOffset="55-67" id="DDI-PubMed.28654574.s3.e0" text="capecitabine" /><entity charOffset="72-81" id="DDI-PubMed.28654574.s3.e1" text="celecoxib" /><pair ddi="false" e1="DDI-PubMed.28654574.s3.e0" e2="DDI-PubMed.28654574.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s3.e0" e2="DDI-PubMed.28654574.s3.e1" /></sentence><sentence text="" /><sentence text="The current report describes the outcomes of 5 patients with thymic neoplasms treated on a drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies (NCT01705106) conducted at the University of Chicago, plus a sixth patient treated with the same regimen outside of the protocol"><entity charOffset="122-134" id="DDI-PubMed.28654574.s5.e0" text="capecitabine" /><entity charOffset="139-148" id="DDI-PubMed.28654574.s5.e1" text="celecoxib" /><pair ddi="false" e1="DDI-PubMed.28654574.s5.e0" e2="DDI-PubMed.28654574.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s5.e0" e2="DDI-PubMed.28654574.s5.e1" /></sentence><sentence text="" /><sentence text="Six patients with thymic neoplasms were treated with capecitabine 1000 mg/m twice daily and celecoxib 200 mg twice daily, day 1 to day 14 on a 21-day cycle"><entity charOffset="53-65" id="DDI-PubMed.28654574.s7.e0" text="capecitabine" /><entity charOffset="92-101" id="DDI-PubMed.28654574.s7.e1" text="celecoxib" /><pair ddi="false" e1="DDI-PubMed.28654574.s7.e0" e2="DDI-PubMed.28654574.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s7.e0" e2="DDI-PubMed.28654574.s7.e1" /></sentence><sentence text=" This included 3 patients with thymic carcinoma, 1 with thymic neuroendocrine tumor, and 2 with thymomas" /><sentence text=" Objective response rates were noted in 3 of 6 patients" /><sentence text=" Two of the 3 thymic carcinoma patients had complete responses, and the third had a partial response" /><sentence text=" Best response for the other patients included stable disease for both thymoma patients and progressive disease for the thymic neuroendocrine patient" /><sentence text=" Other than grade 3 palmar-plantar erythrodysesthesia, which developed in 4 of 6 patients and required dose reductions, the regimen was well tolerated" /><sentence text="" /><sentence text="This case series suggests that capecitabine plus celecoxib may be an effective and well-tolerated treatment option for patients with thymic carcinoma"><entity charOffset="31-43" id="DDI-PubMed.28654574.s14.e0" text="capecitabine" /><entity charOffset="49-58" id="DDI-PubMed.28654574.s14.e1" text="celecoxib" /><pair ddi="false" e1="DDI-PubMed.28654574.s14.e0" e2="DDI-PubMed.28654574.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s14.e0" e2="DDI-PubMed.28654574.s14.e1" /></sentence><sentence text=" Further studies should be carried out to establish the efficacy of capecitabine plus celecoxib in thymic carcinoma, and to determine whether monotherapy with capecitabine would be similarly effective"><entity charOffset="68-80" id="DDI-PubMed.28654574.s15.e0" text="capecitabine" /><entity charOffset="86-95" id="DDI-PubMed.28654574.s15.e1" text="celecoxib" /><entity charOffset="159-171" id="DDI-PubMed.28654574.s15.e2" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.28654574.s15.e0" e2="DDI-PubMed.28654574.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28654574.s15.e0" e2="DDI-PubMed.28654574.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28654574.s15.e0" e2="DDI-PubMed.28654574.s15.e2" /><pair ddi="false" e1="DDI-PubMed.28654574.s15.e1" e2="DDI-PubMed.28654574.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28654574.s15.e1" e2="DDI-PubMed.28654574.s15.e2" /></sentence><sentence text="" /></document>